(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 34.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Prothena Public Co's revenue in 2024 is $91,370,000.On average, 5 Wall Street analysts forecast PRTA's revenue for 2024 to be $1,099,550,273, with the lowest PRTA revenue forecast at $48,348,410, and the highest PRTA revenue forecast at $2,686,022,750. On average, 5 Wall Street analysts forecast PRTA's revenue for 2025 to be $7,415,464,167, with the lowest PRTA revenue forecast at $4,096,721,898, and the highest PRTA revenue forecast at $16,116,136,500.
In 2026, PRTA is forecast to generate $11,583,956,593 in revenue, with the lowest revenue forecast at $6,500,175,055 and the highest revenue forecast at $15,059,455,150.